Orientin alleviates the inflammatory response in psoriasis like dermatitis in BALB/c mice by inhibiting the MAPK signaling pathway

Int Immunopharmacol. 2024 Jun 15:134:112261. doi: 10.1016/j.intimp.2024.112261. Epub 2024 May 17.

Abstract

Background: Psoriasis, a chronic inflammatory condition of the skin, is characterized by an atypical proliferation of epidermal keratinocytes and immune cell infiltration. Orientin is a flavonoid monomer with potent anti-inflammatory activities. However, the therapeutic effects of orientin on psoriasis and the underlying mechanisms have not been elucidated.

Objective: To investigate the therapeutic effect of orientin on psoriasis and the underlying mechanisms using network pharmacology and experimental studies.

Methods: A psoriasis-like mouse model was established using imiquimod (IMQ). Lipopolysaccharide (LPS) was used to stimulate the RAW264.7 and HaCaT cells in vitro. The therapeutic effects of orientin and the underlying mechanism were analyzed using histopathological, immunohistochemical, quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assay, flow cytometry, and western blotting analyses.

Results: Orientin ameliorated skin lesions and suppressed keratinocyte proliferation and immune cell infiltration in the IMQ-induced psoriasis-like mouse model. Additionally, orientin inhibited the secretion of the pro-inflammatory factors interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, IL-8, IL-17, and IL-23 in the psoriasis-like mouse model and LPS-induced RAW264.7 and HaCaT cells. Furthermore, orientin mitigated the LPS-induced upregulation of reactive oxygen species and downregulation of IL-10 and glutathione levels. Orientin alleviated inflammation by downregulating the MAPK signaling pathway.

Conclusion: Orientin alleviated psoriasis-like dermatitis by suppressing the MAPK signaling pathway, suggesting that orientin is a potential therapeutic for psoriasis.

Keywords: Inflammation; MAPK; Orientin; Oxidative Stress; Psoriasis.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents* / pharmacology
  • Anti-Inflammatory Agents* / therapeutic use
  • Cell Line
  • Cell Proliferation / drug effects
  • Cytokines* / metabolism
  • Dermatitis / drug therapy
  • Dermatitis / immunology
  • Dermatitis / pathology
  • Disease Models, Animal*
  • Flavonoids* / pharmacology
  • Flavonoids* / therapeutic use
  • Glucosides* / pharmacology
  • Glucosides* / therapeutic use
  • HaCaT Cells*
  • Humans
  • Imiquimod*
  • Keratinocytes* / drug effects
  • Lipopolysaccharides*
  • MAP Kinase Signaling System* / drug effects
  • Male
  • Mice
  • Mice, Inbred BALB C*
  • Psoriasis* / chemically induced
  • Psoriasis* / drug therapy
  • Psoriasis* / immunology
  • Psoriasis* / pathology
  • RAW 264.7 Cells
  • Reactive Oxygen Species / metabolism
  • Skin / drug effects
  • Skin / immunology
  • Skin / pathology

Substances

  • Imiquimod
  • Anti-Inflammatory Agents
  • Flavonoids
  • orientin
  • Cytokines
  • Lipopolysaccharides
  • Glucosides
  • Reactive Oxygen Species